In summary, although our study is limited by the depth of molecular analyses and the absence of additional genetic alterations most commonly observed in MPNSTs, such as Cdkn2a or Tp53 loss, it provides a robust foundation for further refinement of sporadic non-NF1 based MPNST modeling. This evidence concerns the gene CDKN2A and malignant peripheral nerve sheath tumor.